“Varicella vaccine passage extension (VAR-PE)” process made available the varicella zoster virus (VZV)-containing vaccines. The research evaluated the varicella commercial vaccine (VAR), randomised 1:1 in 600 healthy children of 20-23 months, administered concurrently with the measles-mumps-rubella (MMR) vaccine, for immunogenicity, efficacy, and tolerability of a VAR-PE method. The 6 weeks post dose 1 seroconversion average in the PP population for both groups was 100%.
VZV antibody reaction rates and GMTs of VZV antibodies to VAR-PE were comparable to those induced by VAR 6 weeks post dose 1. Adverse effects (AEs) were registered by 81.3% of participants Post Dose 1 and 67.9% Postcode 2 from Day 1 to Day 42. Injection-site AEs specific to varicella vaccination were registered by 31.1 percent and 29.7 percent of participants in the VAR-PE and VAR classes, respectively, from Day 1 to Day 42 Postdose 1, and by 25.7 percent and 25.5 percent of participants in the VAR-PE and VAR groups, respectively, from Day 1 to Day 42 Postdose 2. Systemic adverse events (AEs) were relatively similar between the two vaccine types, with the exception of pyrexia and otitis media being higher in VAR-PE and diarrhoea and teething being higher in VAR.
Reference: https://www.tandfonline.com/doi/full/10.1080/21645515.2020.1743122
